0.30p+0.01 (+5.26%)23 Feb 2024, 13:36
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Nuformix PLC Fundamentals

Company NameNuformix PLCLast Updated2024-02-23
IndustryBiotechnologySectorHealthcare
Shares in Issue744.309 mMarket Cap£2.23 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.0408Cash Equity Ratio0.0849
Quick Ratio3.4504Current Ratio3.45
Price To Book Value0.5057ROCE0

Nuformix PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Nuformix PLC Company Financials

Assets202320222021
Tangible Assets0£438.00£957.00
Intangible Assets£4.08 m£4.15 m£4.19 m
Investments000
Total Fixed Assets£4.08 m£4.15 m£4.19 m
Stocks000
Debtors£48,938.00£171,659.00£17,518.00
Cash & Equivalents£202,548.00£464,095.00£1.67 m
Other Assets000
Total Assets£4.42 m£4.98 m£6.01 m
Liabilities202320222021
Creditors within 1 year£222,990.00£237,861.00£324,624.00
Creditors after 1 year000
Other Liabilities000
Total Liabilities£222,990.00£237,861.00£324,624.00
Net assets£4.20 m£4.74 m£5.69 m
Equity202320222021
Called up share capital£744,309.00£615,609.00£591,609.00
Share Premium£6.66 m£6.50 m£6.38 m
Profit / Loss-£927,972.00-£1.27 m-£1.38 m
Other Equity£4.20 m£4.74 m£5.69 m
Preference & Minorities000
Total Capital Employed£4.20 m£4.74 m£5.69 m
Ratios202320222021
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.04081.04081.0408
Cash / Equity0.08490.08490.0849
EPS£-0.00£-0.00£-0.00
Cash Flow202320222021
Cash from operating activities-£546,232.00-£1.35 m-£845,166.00
Cashflow before financing-£261,547.00-£1.21 m£1.08 m
Increase in Cash-£261,547.00-£1.21 m£1.13 m
Income202320222021
Turnover0£50,000.00£195,550.00
Cost of sales0£1,695.00£62,307.00
Gross Profit0£48,305.00£133,243.00
Operating Profit-£927,972.00-£1.27 m-£1.37 m
Pre-Tax profit-£927,972.00-£1.27 m-£1.38 m

Nuformix PLC Company Background

SectorHealthcare
ActivitiesNuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.
Latest Interim Date30 Jun 2023
Latest Fiscal Year End Date3 Jan 2024

Nuformix PLC Directors

AppointedNamePosition
2018-08-17Mr. Anthony Henry Reeves Non-Executive Director
2022-05-31Dr. Alastair James RiddellExecutive Director,Chairman
2021-05-24Dr. Karl Keegan Non-Executive Director
2020-01-31Professor Francis John LidgeyNon-Executive Director
2018-08-17Mr. Pascal HughesExecutive Director,Chief Executive Officer
2020-02-05Mr. David Joszef TapolczayNon-Executive Director,Chairman
2024-01-15Dr. Daniel John GoodingExecutive Director
2019-09-10Mr. Kirk Siderman-WolterNon-Executive Director
2022-08-01Dr. Joanne HollandExecutive Director,Chief Scientific Officer
2024-01-15Mrs. Madeleine Elizabeth KennedyNon-Executive Director
2024-01-15Dr. Julian GilbertNon-Executive Director,Chairman
2021-11-09Dr. Anne BrindleyExecutive Director,Chief Executive Officer

Nuformix PLC Contact Details

Company NameNuformix PLC
Address60 Gracechurch Street, 6th Floor, London, EC3V 0HR
Telephone+44 1223627222
Websitehttps://www.nuformix.com

Nuformix PLC Advisors

StockbrokerWhitman Howard
Phone+44 2076591234
SolicitorShakespeare Martineau LLP
Phone+44 1908304443
AuditorMoore Stephens LLP
Phone+44 2073349191
Fax+44 2072483408
BankHSBC Bank PLC
Financial PR AdviserGable Communications
Phone+44 2071937463
Financial AdviserEGR Broking Limited
Phone+44 2036979495
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
StockbrokerEGR Broking Limited
Phone+44 2036979495